Literature DB >> 28819282

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

A Nazha1, K Al-Issa1, B K Hamilton1, T Radivoyevitch2, A T Gerds1, S Mukherjee1, V Adema2, A Zarzour1, N Abuhadra1, B J Patel1, C M Hirsch2, A Advani1, B Przychodzen2, H E Carraway1, J P Maciejewski2, M A Sekeres1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28819282     DOI： 10.1038/leu.2017.266

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

Review 1.  Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Authors:  Aziz Nazha; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

2.  Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Authors:  Lingxu Jiang; Lu Wang; Chuying Shen; Shuanghong Zhu; Wei Lang; Yingwan Luo; Hua Zhang; Wenli Yang; Yueyuan Han; Liya Ma; Yanling Ren; Xinping Zhou; Chen Mei; Li Ye; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Authors:  Katja Sockel; Uwe Platzbecker
Journal:  Drugs       Date:  2018-12       Impact factor: 9.546

4.  Lowering the boom on lower-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Bhumika J Patel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  Integrating patient-centered factors in the risk assessment of MDS.

Authors:  Rena J Buckstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Therapy for lower-risk MDS.

Authors:  Hetty E Carraway; Caner Saygin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Authors:  Naoki Shingai; Yuka Harada; Hiroko Iizuka; Yosuke Ogata; Noriko Doki; Kazuteru Ohashi; Masao Hagihara; Norio Komatsu; Hironori Harada
Journal:  Int J Hematol       Date:  2018-10-23       Impact factor: 2.490

Review 9.  Rethinking clinical trial endpoints in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; David P Steensma
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

Review 10.  Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration.

Authors:  Tzu-Hua Chen-Liang
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.